ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02229903
Recruitment Status : Completed
First Posted : September 3, 2014
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Brainsway

Brief Summary:
The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS) treatment in subjects with OCD. The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a predetermined frequency. The Brainsway DTMS study is a randomized, 10 week, double blind, multi-center trial comparing active DTMS treatment to sham treatment.

Condition or disease Intervention/treatment Phase
Obsessive Compulsive Disorder Device: Active DTMS Treatment Device: Sham Treatment Phase 3

Detailed Description:
The OCD study will compare one group of OCD subjects receiving DTMS treatment (HAC-coil) to a second group of OCD subjects receiving sham treatment (sham coil). The treatment group will receive 5 weeks of daily DTMS treatments followed by 4 treatments in week 6, for a total of 29 treatment sessions. The control group will receive the same treatments with a sham coil. Subjects may continue to take SSRI medications (if prescribed) and any other antidepressant medications will be tapered down prior to the first treatment. SSRI medications approved for OCD include Fluoxetine (Prozac, Sarafem, Symbyax), Fluvoxamine (Luvox, Luvox CR), Paroxetine (Paxil, Paxil CR, Pexeva) and Sertraline (Zoloft). Efficacy will be assessed using the Yale-Brown Obsessive Compulsive Scale score (YBOCS), as well as other efficacy scales. Safety will be assessed by monitoring of adverse events, vital signs, physical and neurological examination and using certain safety questionnaires.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects
Study Start Date : September 2014
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Active DTMS Treatment
Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
Device: Active DTMS Treatment
H-coil Deep TMS 29 TMS treatments over 6 weeks.

Sham Comparator: Sham Treatment
The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
Device: Sham Treatment
29 treatments over 6 weeks.
Other Name: Deep TMS Sham treatment




Primary Outcome Measures :
  1. Yale Brown Obsessive Compulsive Scale (YBOCS) score [ Time Frame: 6 Weeks ]
    The primary objective of the study is to compare the change in Yale Brown Obsessive Compulsive Scale (YBOCS) scores from baseline to the 6 week (post-randomization) visit, between the two treatments groups.


Secondary Outcome Measures :
  1. Yale Brown Obsessive Compulsive Scale (YBOCS), Sheehan Disability Scale (SDS), Clinical Global Impression - Severity Scale (CGI-S), Clinical Global Impression - Improvement Scale (CGI-I) [ Time Frame: 6 Weeks and 10 weeks ]

    The secondary effectiveness objectives of the study are:

    i. Change from baseline to 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) (and other assessment scale) scores, between treatment groups.

    ii. Response rate at 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) score from baseline, between treatment groups; iii.Partial Response rate at 6 weeks in Yale Brown Obsessive Compulsive Scale (YBOCS) score, between treatment groups; iv. Change from baseline to 10 weeks in above scales. v. Remission rates at 6 weeks between treatment groups.



Other Outcome Measures:
  1. Number of adverse events, changes in vitals signs, physical and neurological results, changes in suicide scale and changes in cognitive scales [ Time Frame: 10 Weeks ]

    Safety of the DTMS treatment as defined by maintained subject baseline, pre-treatment, physical and neurological examinations and lack of significant increase in suicide ideation measured by:

    • Vital signs
    • Physical and neurological examination
    • Scale for Suicide Ideation
    • Cognitive evaluation using the Mini-Mental State Exam (MMSE), Buschke Selective Reminding Test (BSRT) and Autobiographical Memory Interview - Short Form (AMI-S) scales
    • Any other adverse events (AEs).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 68 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- • Outpatients

  • Men and women 22-68 years of age.
  • Subjects diagnosed as suffering from OCD according to the DSM-IV-TR.
  • Subjects with at least moderate OCD, rating a YBOCS score of >20.
  • Subjects are maintained on SSRI medication at at least a therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial and/or subjects are maintained on psychotherapeutic behavioral intervention therapy (subjects undergoing CBT treatment must be in the maintenance stage (i.e., not during the assessment or skills acquisition or training stages).
  • Subjects with negative responses on the Transcranial Magnetic Stimulation Safety Screening questionnaire (TASS).
  • According to the treating physician the subject is compliant with taking medication, if applicable.
  • Subject is capable and willing to provide informed consent.
  • Subject is able to adhere to the treatment schedule.

Exclusion Criteria:

- • Subjects diagnosed according to the SCID I as suffering from any other Axis I diagnosis as the primary diagnosis.

  • Subjects diagnosed according to the SCID II as suffering from severe Personality Disorder (excluding Obsessive Compulsive Personality Disorder) or hospitalized due to exacerbation related to borderline personality disorder.
  • Present suicidal risk as assessed by the investigator using the Scale for Suicide Ideation (SSI), brief mental status exam and psychiatric interview or significant suicide risk based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the past year.
  • Subject has a history of epilepsy or seizure (EXCEPT those therapeutically induced by ECT) or history of such in first degree relatives.
  • Subject has an increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
  • Subject has a history of head injury necessitating cranial surgery or prolonged coma.
  • Subject has a history of any metal in the head including the eyes and ears (outside the mouth).
  • Subject has known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.
  • Subject has a history of significant hearing loss.
  • Subjects with significant neurological disorder or insult including, but not limited to:
  • Any condition likely to be associated with increased intracranial pressure
  • Subject has a history of substance abuse including alcoholism within the past 6 months (except nicotine and caffeine).
  • Inadequate communication with the patient.
  • Subject is currently participating in another clinical study or enrolled in another clinical study within 30 days prior to this study.
  • Subjects who suffer from an unstable physical, systemic and metabolic disorder such as unstabilized blood pressure or acute, unstable cardiac disease.
  • Subject is currently on any antidepressant medication other than SSRIs.
  • Subject is currently on Clomipramine
  • Subject has had previous treatment with TMS
  • Women who are breast-feeding
  • Women who are pregnant or with suspected pregnancy
  • Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02229903


Locations
United States, California
University of California (UCLA)
Los Angeles, California, United States, 90095
University of California
San Diego, California, United States, 92093
United States, Florida
University of Florida College of Medicine
Gainesville, Florida, United States, 32603
Advanced Mental Health Care Inc. - Juno Beach
Juno Beach, Florida, United States, 33408
Advanced Mental Health Care Inc. - Royal Palm Beach
Royal Palm Beach, Florida, United States, 33411
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, New York
Neuropharmacology Services
New York, New York, United States, 10021
Mount Sinai Hospital
New York, New York, United States, 10029
TMS Hope Center of Long Island
New York, New York, United States, 11777
United States, Ohio
Lindner Center of HOPE, University of Cincinnati College of Medicine
Mason, Ohio, United States, 45040
Canada, Ontario
Center for Addiction and Mental Health (CAMH)
Toronto, Ontario, Canada
Israel
Tel Hashomer Hospital
Tel Hashomer, Israel, 52621
Sponsors and Collaborators
Brainsway
Investigators
Principal Investigator: Joseph Zohar, Prof Tel Hashomer Hospital
Principal Investigator: Abraham Zangen, Prof Soroka University Medical Center

Responsible Party: Brainsway
ClinicalTrials.gov Identifier: NCT02229903     History of Changes
Other Study ID Numbers: CTP-OCD-01
First Posted: September 3, 2014    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: February 2017

Keywords provided by Brainsway:
OCD

Additional relevant MeSH terms:
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Personality Disorders
Mental Disorders
Anxiety Disorders